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Abstract. Medical treatment and chemotherapy are sel-
dom successful in achieving objective tumour reduction
in patients with metastatic neuroendocrine tumours.
Treatment with the radiolabelled somatostatin analogue
[90Y-DOTA0,Tyr3]octreotide may result in partial remis-
sions in 10–25% of patients. The newer analogue
[DOTA0,Tyr3]octreotate (octreotate) has a ninefold high-
er affinity for the somatostatin receptor subtype 2 as
compared with [DOTA0,Tyr3]octreotide. Also, labelled
with the beta- and gamma-emitting radionuclide 177Lu, it
has proved very successful in achieving tumour regres-
sion in animal models. The effects of 177Lu-octreotate
therapy were studied in 35 patients with neuroendocrine
gastro-entero-pancreatic (GEP) tumours who underwent
follow-up for 3–6 months after receiving their final dose.
Patients were treated with doses of 100, 150 or 200 mCi
177Lu-octreotate, to a final cumulative dose of 600–
800 mCi, with treatment intervals of 6–9 weeks. Nausea
and vomiting within the first 24 h after administration
were present in 30% and 14% of the administrations, re-
spectively. WHO toxicity grade 3 anaemia, leucocytope-
nia and thrombocytopenia occurred after 0%, 1% and
1% of the administrations, respectively. Serum creatinine
and creatinine clearance did not change significantly.
The effects of the therapy on tumour size were evaluable
in 34 patients. Three months after the final administra-
tion, complete remission was found in one patient (3%),
partial remission in 12 (35%), stable disease in 14 (41%)
and progressive disease in seven (21%), including three
patients who died during the treatment period. Tumour
response was positively correlated with a high uptake on
the octreoscan, limited hepatic tumour mass and a high
Karnofsky Performance Score. Because of the limited ef-
ficacy of alternative therapies, many physicians currently
adopt an expectant attitude when dealing with patients
with metastatic GEP tumours. However, in view of the
high success rate of therapy with 177Lu-octreotate and
the absence of serious side-effects, we advocate its use in
patients with GEP tumours without waiting for tumour
progression.
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Introduction
Neuroendocrine gastro-entero-pancreatic (GEP) tu-
mours, which comprise pancreatic islet cell tumours,
non-functioning neuroendocrine pancreatic tumours and
carcinoids, are usually slow growing. If the tumour is lo-
calized, the therapy of choice is surgery. When a meta-
static tumour causes a syndrome by hormonal overpro-
duction (i.e. carcinoid syndrome, hypergastrinaemia),
treatment with somatostatin analogues results in symp-
tomatic relief in most cases. In terms of objective tumour
reduction (complete and partial remission), however,
treatment with somatostatin analogues is seldom suc-
cessful, whether or not it is given in combination with
interferon-α [1, 2, 3].
A new development in cytoreductive therapy for GEP
tumours is the use of radiolabelled somatostatin ana-
logues. Initial studies with high doses of [111In-
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DTPA0]octreotide (111In-octreotide; Octreoscan) in pa-
tients with metastatic neuroendocrine tumours were en-
couraging, although partial remissions were exceptional
[4, 5]. However, 111In-coupled peptides are not ideal for
peptide receptor radionuclide radiotherapy (PRRT) be-
cause of the small particle range and therefore short tis-
sue penetration. Therefore, another radiolabelled so-
matostatin analogue, [90Y-DOTA0,Tyr3]octreotide, was
developed. Using this compound, partial remissions have
been reported in 10–25% of patients with neuroendo-
crine tumours [6, 7, 8].
Recently, it was reported that the somatostatin ana-
logue [DOTA0,Tyr3]octreotate has a ninefold higher af-
finity for the somatostatin receptor subtype 2 as com-
pared with [DOTA0,Tyr3]octreotide [9]. Also, labelled
with the beta- and gamma-emitting radionuclide 177Lu,
this compound was shown to be very successful in
achieving tumour regression and animal survival in a rat
model [10]. In a comparison in patients, we found that
the uptake of radioactivity, expressed as a percentage 
of the injected dose of [177Lu-DOTA0,Tyr3]octreotate
(177Lu-octreotate), was comparable to that after 111In-oct-
reotide for kidneys, spleen and liver, but was three- to
fourfold higher for four of five tumours [11].We con-
cluded that 177Lu-octreotate potentially represents an im-
portant improvement because of (a) the higher absorbed
doses that can be delivered to most tumours with about
equal doses to potentially dose-limiting organs and (b)
the lower tissue penetration range of 177Lu as compared
with 90Y, which may be especially important for small
tumours.
In this study we present the first data on the side-
effects as well as the antitumoral effects of 177Lu-
octreotate therapy in 35 patients with GEP tumours,
who had a follow-up of 3–6 months after receiving their
final dose.
Materials and methods
Patients. Thirty-five patients with GEP tumours were studied. All
patients had tumour uptake on the octreoscan preceding the thera-
py that was at least as high as the uptake in the normal liver tissue.
None of the patients had received prior treatment with other 
radiolabelled somatostatin analogues. Eight patients used Sand-
ostatin s.c.; this medication was discontinued from 1 day before 
to 1 day after the treatment. Prerequisites for treatment were: 
Hb ≥6 mmol/l, WBC ≥2×109/l, platelets ≥80×109/l, creatinine
≤150 µmol/l and Karnofsky Performance Score ≥50.
All patients gave written informed consent to participate in the
study, which was approved by the medical ethical committee of
the hospital.
Methods. [DOTA0,Tyr3]octreotate was obtained from Mallinck-
rodt, St Louis, Mo., USA. 177LuCl3 was obtained from NRG, 
Petten, the Netherlands and Missouri University Research Reactor
(MURR), Missouri, Mo., USA, and was distributed by IDB, 
Baarle-Nassau, the Netherlands. 177Lu-octreotate was prepared as
described previously [11].
Granisetron 3 mg was injected i.v. and an infusion of amino
acids (lysine 2.5%, arginine 2.5% in 1 l 0.9% NaCl; 250 ml/h) was
started 30 min before the administration of the radiopharmaceuti-
cal and lasted up to 3.5 h afterwards. The radiopharmaceutical was
co-administered via a second pump system. The treatment doses
of 100 mCi were injected in 20 min and those of 150 and 200 mCi
were injected in 30 min. The interval between treatments was 6–9
weeks. Patients were treated up to a cumulative dose of
750–800 mCi (27.8–29.6 GBq) (corresponding to a radiation dose
to the bone marrow of 2 Gy) [11], unless dosimetric calculations
indicated that the radiation dose to the kidneys would then exceed
23 Gy; in these cases the cumulative dose was reduced to
600–700 mCi.
Routine haematology, liver and kidney function tests, hormone
measurements and serum tumour markers were measured 1 week
prior to each therapy, as well as at follow-up visits. EORTC quali-
ty of life forms (QLQ-C30) [12] were filled out by the patients at
each visit.
CT or MRI scanning was done within 3 months before the first
therapy, and 6–8 weeks, 3 months and 6 months after the last
treatment.
In vivo measurements. The tumours on the CT or MRI scans were
measured and scored according to the WHO solid tumour re-
sponse criteria. The uptake on the pretreatment octreoscans was
scored visually on planar images on a 4-point scale: grade 1, lower
than normal liver tissue uptake; grade 2, equal to normal liver tis-
sue uptake; grade 3, greater than normal liver tissue uptake; grade
4, higher than normal spleen/kidney uptake.
Statistics. Analysis of variance (ANOVA), paired t tests and chi-
square tests were used. P values <0.05 were considered significant.
Results
The study population comprised 14 men and 21 women
with a mean age of 54 years(range 19–78 years). Twelve
had carcinoid tumour, 12 neuroendocrine pancreatic tu-
mour, 8 neuroendocrine tumour of unknown origin and 3
gastrinoma. Twelve patients had been operated in the
past, 1 had had radiotherapy, 3 had had chemotherapy
and 14 had been treated with octreotide (Sandostatin).
Sixteen of the 35 (46%) patients had documented pro-
gressive disease within 1 year before the start of the ther-
apy. Cycle doses were 100 mCi in seven patients,
150 mCi in 14 and 200 mCi in the remaining 14. Higher
dosages were not administered, since 200 mCi 177LuCl3
is typically bound to 180–300 µg [DOTA0,Tyr3]octreo-
tate, and higher doses would result in a lower percentage
tumour uptake owing to receptor saturation. In 30 pa-
tients, the final intended cumulative dose of 600–
800 mCi was administered. Three of the five remaining
patients had progressive disease and died before com-
pleting their treatment; the other two patients, who were
both elderly, stopped their treatment after reaching a cu-
mulative dose of 600 mCi because of the burden they felt
the treatment to be.
Nausea and vomiting within the first 24 h after the ad-
ministration were present in 30% and 14% of the admin-
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istrations, respectively, and were independent of the ad-
ministered dose. Some abdominal pain was noticed dur-
ing 11% of the administrations, especially in patients
with liver metastases. Increased, mild hair loss was pres-
ent in 17 of the 35 patients; hair regrowth had occurred
at follow-up 3 and 6 months after the final administra-
tion.
WHO toxicity grade 2 or 3 anaemia (Hb 4.95–6.2 or
4.0–4.9 mmol/l, respectively), leucocytopenia (WBC
2.0–2.9 or 1.0–1.9×109/l, respectively) and thrombocy-
topenia (platelets 50–74.9 or 25.0–49.9×109/l, respec-
tively) occurred after 8% and 0%, 5% and 1%, and 3%
and 1% of the administrations, respectively. Toxicity
grade 2 or 3 leucocytopenia or thrombocytopenia oc-
curred in two out of three (67%) patients who had had
previous chemotherapy, as against seven out of 32
(22%) patients who had not. Mean haematological pa-
rameters rose again during the follow-up after the final
administration. Serum creatinine, creatinine clearance
and serum HbA1c did not change significantly (data not
shown). In patients without thyroid hormone medica-
tion, serum TSH and fT4 levels did not change. In wom-
en, serum LH and FSH concentrations did not change
significantly; in men, serum testosterone decreased and
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Table 1. Tumour responses in
34 patients, 3 months after the
final administration of 177Lu-
octreotate. Three patients with
PD died before reaching their
final dose
Tumour type Response Total
CR PR SD PD
Carcinoid 4 (33%) 6 (50%) 2 (17%) 12
NE pancreas 1 (8%) 1 (8%) 7 (58%) 3 (25%) 12
NE unknown origin 4 (57%) 1 (14%) 2 (29%) 7
Gastrinoma 3 (100%) 3
Total 1 (3%) 12 (35%) 14 (41%) 7 (21%) 34
Fig. 1. A–C Planar scans of the abdomen, 3 days after the injec-
tion of 200 mCi 177Lu-octreotate in a patient with liver metastases
of an operated neuroendocrine pancreatic tumour. A After the first
treatment; B after the second treatment; C after the fourth treat-
ment. Note the loss of intensity of uptake in the liver lesions (ar-
rows in A). This sign virtually always indicates a tumour volume
response. D, E CT scans of the same patient: before treatment (D)
and 3 months after the last treatment (E). Tumour (arrows in D) is
not demonstrated on E. Neither MRI nor octreoscan could demon-
strate definite tumour deposits at that time
serum LH concentrations increased significantly. Also
inhibin-B concentrations decreased and serum FSH lev-
els increased significantly.
The effects of the therapy on tumour size were evalu-
able in 34 patients. Three months after the final adminis-
tration (on average 9 months from the start of the treat-
ment), a complete remission (CR), evaluated with CT
scanning, MRI and somatostatin receptor imaging, was
found in one patient (3%), partial remission (PR) in 12
(35%), stable disease (SD) in 14 (41%) and progressive
disease (PD) in 7 (21%), including the three patients who
died during the treatment period (Table 1) (Figs. 1, 2).
Follow-up evaluation 6 months after the final therapy
was available for 19 of the 34 patients. All seven patients
who had PR after 3 months still had PR after 6 months;
in 10 of the 12 patients with SD, the evaluation was un-
changed, whereas one had a minimal response (MR) and
one had PD.
Tumour response (CR or PR) was significantly more
frequent in patients whose tumours had a high uptake on
the octreoscan [6/7 (86%) with grade 4 uptake vs. 7/27
(26%) with grade 2 or 3 uptake; chi-square test: P<0.05].
Five out of the seven patients (71%) with PD had hepa-
tomegaly and diffuse liver metastases vs 6 out of 27
(22%) with CR, PR or SD (chi-square test: P<0.05). Tu-
mour response was more frequent in patients with docu-
mented PD within 1 year before the start of the treatment
(8/15; 53%) than in those without (5/19; 26%), although
this difference was not statistically significant (P=0.11;
chi-square test). Of the 15 patients with documented PD
before the start of the treatment, 3 (20%) had SD at fol-
low-up. Patients who had a Karnofsky Performance
Score of less than 80 before the treatment more frequent-
ly had PD (5/8; 63%) than those who had higher scores
(2/26; 8%) (P<0.01; chi-square test).
The serum tumour marker chromogranin-A was ele-
vated in 29 patients. During the treatment and follow-up,
there was a clear decrease in serum chromogranin-A
concentrations in patients with PR or CR, whereas these
concentrations were virtually unchanged in patients with
SD, and initially showed an increase in patients with PD
(Fig. 3).
The patient-assessed quality of life, according to the
EORTC-QLQ30 questionnaire, was evaluated in 25 pa-
tients. Ten patients were excluded because of progressive
disease/death (n=5) or missing forms during the follow-
up period (n=5, foreign patients). Scores before the start
of the treatment, after receiving 400–600 mCi 177Lu-oct-
reotate and at follow-up 3 months after the final treat-
ment were evaluated. There were no significant differ-
ences for functional scales or single symptom scales.
The global health scale, on which patients were asked to
assign marks regarding both their general health and
their quality of life, and which ranged from 0 to 100, was
judged as higher than 70 by nine patients (36%) before
the start of the treatment, by 17 (68%) patients during
the treatment and by 16 (64%) patients after the treat-
ment (P<0.05; chi-square test).
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Fig. 2. A, B MRI scans in a
woman with hepatic metastases
of a gastrinoma. Before treat-
ment (A) she was inoperable
because of the size and local-
ization of the metastases. Three
months after completion of her
treatment with 800 mCi 177Lu-
octreotate she had a PR (B).
Note also that the hypertrophy
of the gastric wall (arrow in A)
had diminished. Concomitantly,
serum concentrations of gastrin
(closed dots) and chromogra-
nin-A (open dots) had de-
creased markedly (C). At 6
months the MRI showed no
further regression. The patient
underwent left partial hepatec-
tomy and the two right-sided
lesions were drained and inject-
ed with alcohol. MRI 3 months
after surgery showed further re-
gression of the right-sided le-
sions
Fig. 3. Serum chromogranin-A concentrations during and after
therapy in patients with PR, SD or PD. The reduction in the num-
ber of patients during the course of the follow-up was due to death
or missing values. Note the logarithmic y-axis
other scores mainly addressing symptoms did not change
significantly is likely due to the diversity of symptoms
between patients, the use of Sandostatin by symptomatic
patients and the small size of the patient group.
Many physicians adopt an expectant attitude when
dealing with patients with metastatic GEP tumours ow-
ing to the low success rates of chemotherapy protocols.
However, given that treatment with 177Lu-octreotate re-
sulted in PR (or CR) in 38% of our patients, this attitude
may be questioned. Although there was a (statistically
non-significant) tendency towards more frequent tumour
regression in patients who had documented PD before
the start of the treatment, those of our patients who had
an objective tumour response more frequently had a lim-
ited tumour load. This implies that waiting for tumour
progression might place patients in a worse position, as
PD during or after treatment was more frequent in pa-
tients with an extensive tumour load, especially in the
liver. We therefore advocate treatment with177Lu-octreo-
tate at an earlier stage of metastatic disease, when even
CR may be possible. Another argument in favour of ear-
ly treatment is that neuroendocrine tumours can dediffer-
entiate in the course of the disease, and lose their so-
matostatin receptors, making treatment with radiola-
belled somatostatin analogues impossible. If serious
side-effects of treatment with 177Lu-octreotate remain
absent during longer patient follow-up, such treatment
could also be considered in an adjuvant setting in pa-
tients with neuroendocrine tumours who are operated on
with curative intent.
Lastly, as it has been shown in animal experiments
that 90Y-labelled somatostatin analogues are more effec-
tive for larger tumours and 177Lu-labelled somatostatin
analogues are more effective for smaller tumours [13,
14], combination therapy with 90Y-labelled and 177Lu-la-
belled octreotate may be tried in the near future. Such
therapy might yield even better results than treatment
with either of the radionuclides alone [15].
Acknowledgements. The authors wish to thank all supporting per-
sonnel of the Department of Nuclear Medicine for their expert
help and effort.
References
1. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann
ME. Gastroenteropancreatic endocrine tumours: effect of
Sandostatin on tumour growth. The German Sandostatin Study
Group. Digestion 1993; 54 (Suppl 1):72–75.
2. Janson ET, Oberg K. Long-term management of the carcinoid
syndrome. Treatment with octreotide alone and in combination
with alpha-interferon. Acta Oncol 1993; 32:225–229.
3. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, 
Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H,
Jian R, Genestin E, Hammel P, Rougier P. The antitumoral ef-
fect of the long-acting somatostatin analog lanreotide in neu-
roendocrine tumors. Am J Gastroenterol 2000; 95:3276–3281.
421
European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 3, March 2003
European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 1, January 2003
Discussion
There are few treatment options for metastatic GEP tu-
mours. The use of radiolabelled somatostatin analogues
for tumour regression is a promising new development.
With [90Y-DOTA0,Tyr3]octreotide, PR (or CR) has been
reported in 10–25% of patients with neuroendocrine tu-
mours [6, 7, 8]. In the present study we found objective
tumour shrinkage in 38% of the patients, but PD before
the start of the treatment was documented in only 46% 
of the patients. This last fact is important, because 
documented PD was present in more than 80% of pa-
tients in two of the reported series treated with [90Y-
DOTA0,Tyr3]octreotide [6, 8]. As with chemotherapy, an
objective tumour response after PRRT is more likely in
patients with (fast) growing tumours. Indeed, in our se-
ries we also found a trend towards a more favourable
treatment outcome in patients with documented PD be-
fore the start of the treatment. It may therefore be con-
cluded that the percentage of patients with significant tu-
mour shrinkage in our study might have been even high-
er had the percentage of patients with PD prior to treat-
ment been comparable to that in studies with [90Y-
DOTA0,Tyr3]octreotide. The side-effects of treatment
with 177Lu-octreotate are few and mostly transient, with
mild bone marrow depression as the most common find-
ing. Neither renal nor pituitary function deteriorated in
any of our patients. Other side-effects can be ascribed to
the radiation dose to the testes in men. This dose leads to
significantly lower serum testosterone and inhibin-B lev-
els which in turn give rise to higher serum LH and FSH
concentrations, thereby substantiating that the pituitary
function is unimpaired.
The patient-assessed global health score improved in
30% of patients during the treatment and the follow-up
period. This is an important finding which reflects the
improvement in patient well-being and stresses the scar-
city of side-effects as perceived by patients. The fact that
4. Valkema R, de Jong M, Bakker WH, Breeman WAP, Kooij
PPM, Lugtenburg PJ, de Jong FH, Christiansen A, Kam BLR,
de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning
EP. Phase I study of peptide receptor radionuclide therapy
with [111In-DTPA0]octreotide: the Rotterdam experience. Se-
min Nucl Med 2002; 32:110–122.
5. McCarthy KE, Woltering EA, Espenan GD, Cronin M,
Maloney TJ, Anthony LB. In situ radiotherapy with 111In-
pentetreotide: initial observations and future directions. Can-
cer J Sci Am 1998; 4:94-102.
6. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-
Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-oct-
reotide (90Y-DOTATOC) in the treatment of neuroendocrine tu-
mours: a clinical phase II study. Ann Oncol 2001; 12:941–945.
7. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, 
Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, 
Chinol M, de Braud F. Receptor-mediated radiotherapy with
90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;
28:426–434.
8. Valkema R, Jamar F, Bakker WH, Norenberg J, Smith C, Stolz
B, Kvols L, Pauwels S, Krenning EP. Safety and efficacy of
[Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487;OctreoTher)
peptide receptor radionuclide therapy (PRRT). Preliminary re-
sults of a phase-1 study. Eur J Nucl Med 2001; 28:1025.
9. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt
JS, Macke HR. Affinity profiles for human somatostatin re-
ceptor subtypes SST1-SST5 of somatostatin radiotracers se-
lected for scintigraphic and radiotherapeutic use. Eur J Nucl
Med 2000; 27:273-282.
10. Erion JL, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A.
High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-oct-
reotate in a rat tumor model. J Nucl Med 1999; 40:223P.
11. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW,
Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M,
Krenning EP. [177Lu-DOTA0Tyr3]octreotate: comparison
with [111In-DTPA0]octreotide in patients. Eur J Nucl Med
2001; 28:1319–1325.
12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez A, Filiberti A, Flechtner H, Fleishman SB, de Haes JC.
The European Organization for Research and Treatment of
Cancer QLQ-C30: a quality-of-life instrument for use in inter-
national clinical trials in oncology. J Natl Cancer Inst 1993;
85:365–376.
13. De Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar
M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan
A, Krenning EP. [177Lu-DOTA(0),Tyr3]octreotate for so-
matostatin receptor-targeted radionuclide therapy. Int J Cancer
2001; 92:628–633.
14. De Jong M, Breeman WA, Bernard BF, Bakker WH, Visser
TJ, Kooij PP, van Gameren A, Krenning EP. Tumor response
after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy
in a transplantable rat tumor model is dependent on tumor
size. J Nucl Med 2001; 42:1841–1846.
15. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ,
Breeman WAP, Bakker WH, Smith C, Pauwels S, Krenning
EP. Somatostatin receptor-targeted radionuclide therapy of tu-
mors: preclinical and clinical findings. Semin Nucl Med 2002;
32:133–140.
422
European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 3, March 2003
